4.6 Article

New Quinolinone O-GlcNAc Transferase Inhibitors Based on Fragment Growth

Journal

FRONTIERS IN CHEMISTRY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2021.666122

Keywords

O-GlcNAc; O-GlcNAc transferase; protein glycosylation; fragments growth; molecular docking

Funding

  1. Slovenian Research Agency [50503, P1-0208]
  2. European Union [765581]
  3. Marie Curie Actions (MSCA) [765581] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

The study found that new inhibitors of OGT did not significantly improve its inhibitory effect, using the existing inhibitor F20 as the basis to design a new series of compounds. Although some elongated compounds showed stronger inhibitory effects, they still had disadvantages compared to F20.
O-GlcNAcylation is an important post-translational and metabolic process in cells that must be carefully regulated. O-GlcNAc transferase (OGT) is ubiquitously present in cells and is the only enzyme that catalyzes the transfer of O-GlcNAc to proteins. OGT is a promising target in various pathologies such as cancer, immune system diseases, or nervous impairment. In our previous work we identified the 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives as promising compounds by a fragment-based drug design approach. Herein, we report the extension of this first series with several new fragments. As the most potent fragment, we identified 3b with an IC50 value of 116.0 mu M. If compared with the most potent inhibitor of the first series, F20 (IC50 = 117.6 mu M), we can conclude that the new fragments did not improve OGT inhibition remarkably. Therefore, F20 was used as the basis for the design of a series of compounds with the elongation toward the O-GlcNAc binding pocket as the free carboxylate allows easy conjugation. Compound 6b with an IC50 value of 144.5 mu M showed the most potent OGT inhibition among the elongated compounds, but it loses inhibition potency when compared to the UDP mimetic F20. We therefore assume that the binding of the compounds in the O-GlcNAc binding pocket is likely not crucial for OGT inhibition. Furthermore, evaluation of the compounds with two different assays revealed that some inhibitors most likely interfere with the commercially available UDP-Glo (TM) glycosyltransferase assay, leading to false positive results. This observation calls for caution, when evaluating UDP mimetic as OGT inhibitors with the UDP-Glo (TM) glycosyltransferase assay, as misinterpretations can occur.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available